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Abstract
Background: Breast cancer is one of the oncological diseases in which health-related quality of life (HRQL) has
been most studied. This is mainly due to its high incidence and survival. This paper seeks to: review published
research into HRQL among women with breast cancer in Spain; analyse the characteristics of these studies; and
describe the instruments used and main results reported.
Methods: The databases consulted were MEDLINE, EMBASE, PsycINFO, Dialnet, IBECS, CUIDEN, ISOC and LILACS.
The inclusion criteria required studies to: 1) include Spanish patients, and a breakdown of results where other types
of tumours and/or women from other countries were also included; and, 2) furnish original data and measure
HRQL using a purpose-designed questionnaire. The methodological quality of studies was assessed.
Results: Spain ranked midway in the European Union in terms of the number of studies conducted on the HRQL
of breast cancer patients. Of the total of 133 papers published from 1993 to 2009, 25 met the inclusion criteria.
Among them, only 12 were considered as having good or excellent quality. A total of 2236 women participated in
the studies analysed. In descending order of frequency, the questionnaires used were the EORTC, FACT-B, QL-CA-
Afex, SF-12, FLIC, RSCL and CCV. Five papers focused on validation or adaptation of questionnaires. Most papers
examined HRQL in terms of type of treatment. Few differences were detected by type of chemotherapy, with the
single exception of worse results among younger women treated with radiotherapy. In the short term, better
results were reported for all HRQL components by women undergoing conservative rather than radical surgery.
Presence of lymphedema was associated with worse HRQL. Three studies assessed differences in HRQL by patients’
psychological traits. Psychosocial disorder and level of depression and anxiety, regardless of treatment or disease
stage, worsened HRQL. In addition, there was a positive effect among patients who reported having a “fighting
spirit” and using “denial” as a defence mechanism. One study found that breast cancer patients scored worse than
did healthy women on almost all SF-12 scales.
Conclusion: Research into health-related quality of life of breast-cancer patients is a little developed field in Spain.
Background
Taking both sexes into account, breast cancer is the most
frequent tumour in Europe [1]. It is one of the oncologi-
cal diseases for which it has become almost standard
practice to include the study of the disease’s impact on
health-related quality of life (HRQL) among the priority
research goals [2], particularly in the English-speaking
world [3].
HRQL can be defined as self-perceived aspects of well-
being that are related to or affected by the presence of a
disease or treatment [4]. As a multidimensional con-
struct, it includes perceptions, both positive and nega-
tive, of several dimensions such as physical, emotional,
social and cognitive functioning. It also includes the
negative aspects of somatisation disorder and symptoms
caused by a disease and/or its treatment [5]. Studies
undertaken in different settings or in different countries
might display slight divergences, as HRQL is also modu-
lated by cultural and care patterns.
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of treatment (surgery, radiotherapy, chemotherapy, or a
combination of all three) have a clear influence on the
patient’s subjective perception of the disease. Their
effects on HRQL are also modulated by personality
traits, personal resources, availability and perception of
social and family support [6], as well as by the strong
cultural association between the breast and women’s
self-esteem and sexuality [7].
A recent review of definitions and conceptual models
of HRQL applied to oncological patients classifies
HRQL-measurement instruments validated for use in
cancer patients into two categories. Questionnaires spe-
cifically designed for the disease explore the repercus-
sions of the most usual symptoms and side-effects, and
are appropriate for comparing treatments or changes in
patients. The general instruments are applicable to any
population, and are better suited to studies that seek to
ascertain the disease’s repercussion on HRQL, taking
the general population as reference [8]. Among the for-
mer, the most used in Europe for breast cancer are the
European Organization for Research and Treatment of
Cancer Core Cancer Quality Life Questionnaire
(EORTC QLQ-C30) and its breast-cancer-specific mod-
ule (EORTC-BR23). Among the latter, the Medical
Outcomes Survey Short-Form General Health Survey
(SF-36) is the most widely used [9].
Although breast cancer incidence is lower in Spain
than in other European countries, the number of new
cases, which was estimated at 22985 women in 2006 [1],
has shown a clearly rising trend from the 1980s until the
year 2000 [10]. Spanish women are estimated to have a
6%-9% lifetime risk of developing this tumour [11].
Screening programmes, along with diagnostic and thera-
peutic advances, have led to a steady decline in mortality
rates since the early 1990s, [12,13], and the estimated
survival at five years of diagnosis currently stands at 86%
[14]. Hence, as the number of women living with this
tumour in Spain progressively rises, the study of HRQL
should become a research topic of increasing relevance.
Studies on Spanish breast cancer patients might reflect
specificities that could help improve and focus care in
such women. To this end, we performed a systematic
review of HRQL research targeting breast cancer patients
in Spain, analysing the studies published and instruments
used, and summarizing the main results reported.
Methods
Search strategy
The databases consulted were MEDLINE via PubMed,
EMBASE, PsycINFO, Dialnet, Índice Bibliográfico Espa-
ñol en Ciencias de la Salud (IBECS), CUIDEN, ISOC
and Literatura Latinoamericana y del Caribe en Cien-
cias de la Salud (LILACS). The information found was
supplemented by manual searches based on the refer-
ences cited in the papers initially identified. The MeSH
terms used for the search were as follows: “Quality of
life” AND “Breast Neoplasm” AND “Spain” in PubMed,
EMBASE and PsycINFO, with “Breast Cancer” also
being used as a key word; “Quality of life” AND “Breast
cancer” in Dialnet; “quality” AND “life” AND “cancer”
AND “breast” in IBECS; “quality of life” and “breast can-
cer” and “Spain” as the key words in CUIDEN; “cancer”
AND “breast” AND “quality” AND “life” in ISOC; and
lastly, the terms “Neoplasms of breast”, “Spain” and
“Quality of life” in LILACS.
The search was conducted until August 2009, without
restrictions of language or year of publication. In addi-
tion, the same search strategy used in the two main
databases (PubMed and PsycINFO) was then applied to
each European Union (EU) country. This enabled us to
obtain an idea of Spain’s relative interest in HRQL
research in breast cancer patients within a more interna-
tional context. The systematic search and review pro-
cesses were conducted in accordance with PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) statement criteria.
Inclusion and exclusion criteria
Detailed analyses were solely performed in the case of
papers reporting Spanish studies. Several inclusion criteria
were established. In the case of original papers, studies
were required: 1) to include Spanish patients with breast
cancer; and 2) to furnish original data and measure HRQL
as an independent construct, using a specific question-
naire. We excluded any study in which the results were
not broken down by country of origin when women from
different countries took part, or by type of tumour when
patients with different tumour sites were included.
Data-extraction
Two researchers participated independently and sequen-
tially in the search for and selection of papers. The com-
plete text of the most relevant papers was obtained and
the papers were checked for inclusion criteria. Data on
the authors’ names, year of publication, journal, study
title, questionnaire used to measure HRQL, disease
stage, type of treatment, sample size, and conclusions
about HRQL were collected using a pre-established
structured form set out in the review protocol. The
information extracted by the two reviewers was then
compared and, in case of disagreement, the opinion of a
third reviewer was accepted as the criterion for the
paper being included or not.
Quality assessment
The methodological quality of each of the selected
papers was assessed through two checklists based on the
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studies were assessed using the following criteria: relia-
bility, type of criterion measure, and validity. Each cri-
terion was rated as high, moderate, or low. These three
ratings were condensed into a five-level overall judg-
ment (excellent, good, moderate, fair, or poor) using the
same decision rules as Vodermaier et al.[16].
The remaining papers were assessed according to the
adapted list of Mols and Denollet’s [15] criteria, which
included the following items: 1) a validated questionnaire
is used; 2) a description is included of at least the stage
and type of treatment; 3) inclusion and/or exclusion cri-
teria are described; 4) a information is given about the
degree of the sample selection; 5) a participation rates for
patient groups are described and are more than 75%;
6) study size of at least 100 participants; 7) the process of
data collection is described; 8) the results are compared
between two groups or more; and 9) statistical proof of
the findings is reported. Each item received a score of
one or zero depending on whether or not it fulfilled the
criterion. According to the score obtained, studies were
arbitrarily considered as: excellent (a score of 8-9); good
(6-7); moderate (4-5); fair (2-3); and poor (0-1).
Results
Figure 1 graphically depicts the results of the search
made for each EU country in PubMed and PsycINFO.
W h i l et h eU n i t e dK i n g d o ma n dG e r m a n yw e r et h et w o
countries with most references in both databases, Eastern
European countries generally had very few studies. Spain
occupied a middle-ranking position according to
PubMed, although it was one of the countries with most
references in PsycINFO.
Figure 2 shows the flowchart of the systematic review
process followed in the case of Spanish papers. The
initial search located a total of 133 publications, 82% in
Dialnet, PsycINFO, PubMed and EMBASE. After dupli-
cated references had been discarded, 45 papers were
reviewed, with 25 papers that fulfilled the inclusion cri-
teria being identified. The studies selected are shown in
Table 1. All were published from 1993 to 2009, with the
majority (80%) being published in home-based Spanish-
language journals and only five in international English-
language journals. A total of 2236 women participated
in these studies, with sample sizes ranging from 10 to
583 participants (median, 98). The table included as
Additional File 1 lists the basic characteristics of the stu-
dies identified in the review and provides a summary of
their principal results.
Study objectives
The goal of five studies was the validation or adaptation
of questionnaires [17-21]. Another fourteen papers
focused on studying the repercussions of different thera-
pies on patients’ HRQL. The most common objective
(seven studies) was assessin gt h ep o s s i b l eb e n e f i c i a l
effect of psychotherapy and related factors [22-28]. Inso-
far as medical treatments were concerned, the studies
compared the effects on HRQL of different types of che-
motherapy [29,30], radiotherapy [31] or surgery [32-34].
Similarly, one pilot study examined the efficacy of cardi-
ovascular training on HRQL [35]. In addition, two
papers investigated how HRQL might be influenced by
lymphedema [36,37]. Two research studies considered
variability in patients’ HRQL according to personality
traits [38,39]. Another analysed the influence of HRQL
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Figure 1 Results of the literature search made for each
European Union country in PubMed and PsycINFO. References
identified in the PubMed and PsycINFO databases in European
Union countries, using “Breast cancer”, “Quality of life” and country
name as descriptors.
PubMed    n =  26 
PsycINFO  n =  27 
Dialnet    n =  38 
EMBASE  n =  18 
IBECS    n =    6 
CUIDEN   n =    5 
ISOC    n =    2 
LILACS    n =    0 
Total    n = 122     
Papers excluded: 
• duplicates    n = 25 
• inclusion criteria not met   n = 63 
Papers for review of 
title and abstract 
133 
Papers for review of full text 
45 
Studies included 
25 
Articles excluded: 
• no HRQL-specific results   n = 5 
• no breakdown of results by tumor type n = 6 
• no breakdown of results by country of origin    
n = 2 
• no HRQL-specific questionnaire used  n = 4 
• study with non-Spanish patients   n = 1 
• HRQL not measured    n = 2 
Manual search  n = 11 
Figure 2 Flow chart of process of systematic literature search.
Flow chart of systematic search and review process conducted in
accordance with PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement criteria.
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addressed the overall repercussions of the disease, com-
paring the HRQL of women with breast cancer with
that of healthy women [41].
Questionnaires
Seven HRQL instruments were identified. The EORTC
questionnaires were the most used, in both the original
form QLQ-C30 and the Spanish version, with a specific
module for breast cancer, i.e., the QLQ-BR23 [19-21,25,
31,33-36], and the version adapted for breast cancer
by Toledo in 1993 [17,23,28,29,32,38-40]. Some of
the retrieved studies made express reference to the con-
struction and validation of the breast-specific module [19].
The QLQ-C30 [42] is a self-administered questionnaire
specifically for cancer patients, drawn up and designed to
be used in national and international studies. It is relatively
short, with a mean completion time of 10 minutes. It has a
multidimensional structure, with multi-item scales that
cover four basic HRQL dimensions: disease symptoms and
toxicity; physical functioning and role-physical; psycholo-
gical dimension; and social dimension. It uses Likert-type
scales, and all dimensions are summarized in a final score,
ranging from 0 to 100. In Spain, this questionnaire has
Table 1 Studies on quality of life and breast cancer among Spanish women (1993-2009)
Author(s) [Ref.] Year Objective HRQL assessment
Toledo et al. [17] 1993 Adaptation of EORTC questionnaire EORTC (adapted)
Font [18] 1994 Validation of questionnaire QL-CA-Afex
Ferrero et al. [38] 1994 To explore the relationship between mental adaptation to cancer and QL EORTC (adapted)
Ferrero et al. [39] 1995 Time trend in HRQL and its association with coping with the disease EORTC (adapted)
Blasco et al. [29] 1995 To ascertain the effect on HRQL of autologous treatment with support of peripheral hematopoietic
cells
EORTC (adapted)
QL-CA-Afex
Cagigal Rodríguez
et al. [30]
1995 Comparison of the effect of 3 different types of chemotherapy on HRQL RSCL FLIC
Sprangers et al.
[19]
1996 Validation of questionnaire QLQ-BR23
Toledo et al. [32] 1996 To assess global QL after surgery and before adjuvant treatments EORTC (adapted)
Ruiz et al. [22] 1998 To establish a psychological profile for interventions targeted at improving psychosocial adjustment CCV
Sebastián et al.
[23]
1999 To assess the efficacy of a psychological group intervention program EORTC (adapted)
Condón et al. [36] 2000 To ascertain the impact of lymphedema on QL QLQ-C30 QLQ-
BR23
Arraras et al. [20] 2000 Psychometric study of the QLQ-C30 questionnaire (version 2.0) QLQ-C30
Arraras et al. [21] 2001 Validation of the QLQ-BR23 questionnaire with Spanish sample QLQ-B23
Arraras et al. [33] 2001 To assess QL during treatment QLQ-C30 QLQ-B23
Arraras et al. [34] 2003 To assess QL after a long follow-up period, and study differences in QL by disease stage, surgery,
and adjuvant treatment
QLQ-C30 QLQ-
BR23
Font et al. [24] 2004 To show the efficacy of a psychological group intervention, by analyzing variations in HRQL before
and after therapy
QL-CA-Afex
Cervera et al. [41] 2005 To study the impact of diagnosis of breast cancer on patients’ psychological (psychopathology and
QL) and conjugal adjustment
SF-12
Manos et al. [40] 2005 To analyze the influence of some variables (socio-demographic, type of surgery, social support, and
QL) on body image and self-esteem
EORTC (adapted)
Sánchez et al. [25] 2005 To analyze variables related with withdrawal from a psychological group intervention program QLQ-C30
Herrero et al. [35] 2006 To evaluate the efficacy of a cardiovascular training and resistance program vis-à-vis functional
capacity and QL
QLQ-C30
Yélamos et al. [37] 2007 To compare the QL of women operated on breast cancer with and without lymphedema FACT-B +4
Páez et al. [26] 2007 To compare acceptance and commitment therapy as against cognitive-behavioural therapy. FACT-B
Bellver [27] 2007 To assess the efficacy of two types of group therapy on the emotional state and QL of women with
breast cancer, on termination of adjuvant treatments.
FACT-B
Arraras et al. [31] 2008 To make a prospective assessment of the QL of elderly patients who initiated treatment with
radiotherapy, and compare it with that of a sample of younger patients
QLQ-C30 QLQ-
BR23
Manos [28] 2009 To assess a psychosocial intervention program EORTC (adapted)
EORTC: European Organization for Research and Treatment of Cancer; HRQL: health-related quality of life; QL: quality of life.
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Page 4 of 10been the subject of validation studies, using samples of
patients with cancer of the breast, lung, and head and
neck [20,43].
The breast-cancer-specific QLQ-BR23 questionnaire
[19] assesses areas related to the various treatment mod-
alities (surgery, radiotherapy, chemotherapy, and hormo-
nal therapy). It also assesses other specific aspects of
HRQL in breast cancer patients, such as body image or
sexuality. The questionnaire consists of two parts: level
of functioning and symptoms, each with several indivi-
dual scales and items. One of the studies included here
[17] reported the validation of this questionnaire with a
Spanish population. While Toledo’sq u e s t i o n n a i r e[ 1 7 ]
can be considered as having good construct validity and
internal consistency, neither the version of the EORTC
questionnaire on which it was based, nor the process of
translation, is clearly specified.
Three studies published in 2007 [26,27,37] used the
Functional Assessment of Cancer Therapy-Breast
(FACT-B) quality of life instrument, a questionnaire
made up of 36 items [44] and designed to measure the
HRQL of breast cancer patients in different dimensions.
Like the EORTC questionnaires, the FACT-B comprises
a general instrument for cancer, FACT-G, complemented
by a subscale containing items specific to breast cancer.
The items are grouped into five subscales and are
answered through five-point response scales. The FACT-
B displays good reliability, validity and sensitivity to
change [45].
A third instrument for measuring the HRQL in breast
cancer patients was the QL-CA-Afex, created by Antóni
Font in 1988 and used by the author in two studies, one
of which was a validation study [18,24]. The QL-CA-
Afex comprises 27 items (visual analogue scales) scored
from 0 to 100 and grouped into the following 4 sub-
scales: symptoms; autonomy; familial and social difficul-
ties; and psychological difficulties. Although it is an
instrument for chronic diseases, it has been validated
with breast cancer patients. One of the studies, with a
sample size of only 10 patients, showed a low correla-
tion coefficient with the EORTC instruments [29].
Only one study [30] used the Functional Living Index
Cancer (FLIC), a general HRQL questionnaire for cancer
patients. It evaluates five HRQL dimensions: physical
wellbeing; emotional status; sociability; family situation;
and side-effects of treatment [46]. The FLIC displays
good content validity and is easy to administer. We
failed to find a version of this questionnaire adapted to
and validated for the Spanish population. This same
study [30] also included the version of the Rotterdam
Symptom Checklist (RSCL) geared to the breast cancer
population. The applied version has 38 items using a
4-point Likert-type response scale. It assesses functional
level, symptoms, psychological functioning and sexual
relations, and includes a global HRQL score. Like the
previous questionnaire, the RSCL version used was
neither adapted to nor validated for the Spanish popula-
tion, since the cultural adaptation dates from 1998 [47]
and the study in question was conducted in 1995.
Lastly, two studies used generic HRQL instruments.
O n e[ 4 1 ]u s e dt h eS F - 1 2 ,as h o r tv e r s i o no ft h eS F - 3 6
for the general population. It is a questionnaire which
has been translated into and validated in Spanish. The
SF-12 is made up of 8 subscales (physical health, physi-
cal functioning, bodily pain, general health, vitality,
social functioning, emotional functioning, and mental
health), summarized into two global measures: physical
and mental. Another study [22] used the Quality of Life
Questionnaire (Cuestionario de Calidad de Vida, CCV),
originally developed in Spanish and formally validated in
Spain [48]. It comprises 39 items grouped into 4 sub-
scales: general satisfaction, social support, physical/psy-
chological wellbeing, and absence of work overload/
leisure time.
HRQL results for women with breast cancer
Comparison between patients and healthy women
The only study [41] to address this objective reported
that women with breast cancer displayed greater dete-
rioration in their HRQL, scoring worse on almost all
SF-12 scales.
Treatments and pathology associated with the disease
With respect to the studies about the influence of treat-
ments on HRQL, one [30] reported few differences in
HRQL among the study groups receiving different types
of chemotherapy. As regards the influence of radiother-
apy on the HRQL of persons aged 65 years and over,
one study [31] observed no significant differences prior
to and at 6 months of treatment.
Insofar as psychotherapy was concerned, one study [24]
found better HRQL scores in groups that underwent
some type of psychological group therapy than in those
that received no treatment. Another study [28] observed
less depression and psychological distress among those
treated. However, no relationship was found between
withdrawal from group psychotherapy and HRQL
[25,27]. With respect to the type of psychotherapy, one
paper [26] concluded that acceptance and commitment
therapy yielded better HRQL results than the cognitive
therapy which the control group received.
Studies which assessed the effect of surgery [31,34,41]
reported that conservative surgery had fewer repercus-
sions on HRQL than did radical surgery, and that
HRQL was better for women with sentinel lymph node
biopsy than aggressive axillary surgery. One pilot study
[35] observed significant improvements in global quality
of life and physical functioning in the group of women
who had taken part in a cardiovascular training program
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lymphedema [36,37] both concluded that the presence
of this disorder was associated with worse HRQL.
Psychological traits
The studies that assessed variations in HRQL according
to patients’ psychological traits observed that psychoso-
cial disorders worsened HRQL. In addition, the patients
who best preserved their HRQL used coping strategies
suited to the situation, maintained high self-referential
outcome expectations, and had a certain subjective sen-
sation of control over the disease and its effects [38].
Similarly, significant differences were observed in quality
of life according to the level of depression and anxiety,
regardless of treatment or disease stage [22]. One study
observed a positive effect on HRQL among patients who
reported having a “fighting spirit” and using “denial” as
a defence mechanism, whilst “helpless/hopeless”, “fatal-
ism” and “anxious preoccupation” were associated with
worse HRQL [39].
Methodological quality of the Studies
The additional file provides the summary judgments for
the predefined evaluation criteria. Three of the studies
were considered to be of poor quality according to our
checklist [17,19,21]. Only one paper was evaluated of a
fair quality [29]. Nine were assessed of a moderate quality
[18,22,26,30-32,34,38,40]. Of the remaining studies, ele-
ven were of a good quality [20,23-25,27,28,33,35-37,39]
and one paper was of an excellent quality [41].
Discussion
Our results indicate that research into the HRQL of breast
cancer patients is a little developed field in Spain. Despite
being one of the most populated countries in Western
Europe, Spain ranks among those with the lowest number
of studies addressing this issue. There appear to be two
different publishing patterns among European researchers
active in this field. In the majority of cases, papers are pub-
lished in medical journals, and so PubMed is the biblio-
graphic database with most information. In the case of
Germany and The Netherlands, however, there are similar
numbers of papers in PsycINFO and PubMed, probably
reflecting a more multidisciplinary approach. This would
also seem to apply to Spain. Almost half the studies
included in this review were indexed in PsycINFO. Fewer
papers were published from the medical side. Indeed, the
leading medical bibliographic database, PubMed, con-
tained only four of the studies included in this systematic
review, all of which had been published in international
journals [19,28,31,35].
In this systematic review, we found only 25 papers
that met all inclusion criteria. Five of these, published
between 1993 and 2001, reported validations or cultural
adaptations of questionnaires. Most of the others
examined HRQL by type of treatment, or analysed the
influence of treatments and specific symptoms on
HRQL. A different approach was shown by the three
studies that assessed differences in HRQL by psychologi-
cal traits. Lastly, one report compared the HRQL of
patients with healthy women.
The total number of papers identified was low, despite
the general recommendation to include HRQL as an
outcome in clinical studies involving breast cancer
patients [49], and the fact that HRQL questionnaires are
routinely used in clinical research. This reflects the
scant attention paid to the information afforded by
these instruments. Excluding validation studies, the
instruments most commonly used to measure quality of
life were the EORTC questionnaires (EORTC QLQ-C30
and QLQ-B23) or modified versions of these (13 stu-
dies), with the FACT-B ranking second (3 studies).
Aside from being instruments with adequate psycho-
metric characteristics for measuring HRQL in cancer
patients [19,42,45], they are also the most widely used
in international breast cancer studies [3]. However, only
the EORTC QLQ-C30 and QLQ-B23 have versions vali-
dated in Spanish [20,21,43].
Breast cancer is one of the neoplasms in which the
treatment of choice, surgery, tends to be combined with
other therapeutic strategies, such as chemo-, radio- or
hormonal therapy. Yet, our results show that studies in
Spain aimed at evaluating the effect of treatments on
HRQL are clearly insufficient, and in the case of some
therapies, non-existent. Surgical repercussions on HRQL
are a relatively common issue in international studies [3].
This is because surgery is the initial treatment, at least in
stages I, II and III, for most breast cancer patients [50].
Nevertheless, there is a notable lack of papers in Spain
focused on the effect of surgery on HRQL. Indeed, this
review was able to locate only four papers which made
reference to this topic [31,32,34,41], and only one of
these included the questionnaire scores [41]. This last-
mentioned study compared conservative with radical sur-
gery. It reported better results for the former treatment
i na l lc o m p o n e n t so fH R Q Li nt h es h o r tt e r m .I nt h i s
particular instance, differences were not studied by age
group, though these were reported in a paper from
Canada [51]. Studies undertaken in other countries
(Canada, Germany, and Japan) report contradictory
results for these two surgical approaches in terms of dif-
ferences in HRQL in the long term [51-53]. Only one of
the Spanish studies considered axillary surgery [31].
While the authors reported that HRQL was better among
sentinel lymph node biopsy patients than axillary empty-
ing, they failed to furnish the specific results.
Insofar as radiotherapy was concerned, we found a
single follow-up study [31], which observed no signifi-
cant differences at 6 months of treatment, whether
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should not be the only factor considered when deciding
about oncology treatments, as reported in a study from
the United Kingdom [54].
The most common objective (seven studies) was to
assess the possible beneficial effect of psychotherapy
[22-28]. The improvements in HRQL associated with
psychological therapies observed in Spanish studies are
consistent with the results reported in two papers from
the USA and Australia, respectively [55,56]. Two studies
about the relationship between mental adaptation to can-
cer and HRQL observed differences according to
patients’ age and coping strategies [38,39]. These results
partially agree with those yielded by a study that targeted
older women from the USA [57]. Nevertheless, it is diffi-
cult for our results to be compared with those of other
studies, due to differences in study goals and in HRQL
assessments involving psychological factors [58,59].
Only two studies addressed the negative impact of
lymphedema on the HRQL of Spanish women with
breast cancer [36,37], with findings consistent with two
USA case-control studies [60,61]. In addition, our review
revealed a lack of studies addressing the impact of other
common symptoms, such as pain, fatigue or menopausal
symptoms. This is in contrast with the attention paid to
these items in international literature [3].
Just one study compared the HRQL of breast cancer
patients with that of healthy women [41]. This is an
area of great interest for quantifying the impact of
breast cancer on our society in terms of HRQL. How-
ever, no longitudinal study was identified that was cap-
able of evaluating trends in HRQL over time. In view of
the low fatality rate of breast cancer patients at the pre-
sent time, it would be of great value to have access to
studies designed to assess the long-term repercussions
of the disease on the lives of the women affected.
Some studies (e.g., such as those undertaken by the
Breast Cancer Study Group (http://www.ibcsg.org/), in
which a Spanish team participated [62], and the papers
by Martín et al [63,64]), were excluded in spite of Spanish
patients being included in the sample. This was due to
failure to report the results with a breakdown by country.
Similarly, no consideration was given to studies that
pooled patients with different types of cancer but furn-
ished no specific information about women with breast
cancer [65-69]. Finally, we also excluded studies that
failed to use HRQL-specific instruments [70] or reported
no specific results for this construct [71].
The bibliographic search-and-screening phase showed
us that the term HRQL has not been interpreted by
some Spanish authors in line with the concept of the
multidimensional construct to which it refers. According
to the WHO, quality of life is, “an individual’sp e r c e p -
tion of his/her position in life in the context of the
culture and value systems in which he/she lives, and in
relation to his/her goals, expectations, standards and
concerns“ (1994). This definition stresses the importance
of self-evaluation of cultural factors [72]. It was for this
reason that studies using one-dimensional question-
naires on anxiety, depression or other mental states or
physical symptoms, without considering the multidi-
mensionality of the HRQL construct, were excluded
from the analysis.
This study, aimed at reviewing research on HRQL
among breast cancer patients in Spain, is purely descrip-
tive in nature. The small sample size of existing studies
conducted directly in Spain, with almost half the studies
identified including fewer than 100 women [23,25,26,
29-31,35,36,38-40], renders it difficult to draw conclusions
about the HRQL of Spanish breast cancer patients. In
such a context, publication bias cannot be regarded as a
major problem when compared with the lack of studies
providing data on the subject. A further problem was the
use of HRQL questionnaires that were in-house and/or
not validated for the Spanish population. Lack of informa-
tion on adaptation and translation of questionnaires is an
additional limitation when it comes to comparing, general-
izing and, above all, replicating results. The use of ques-
tionnaires adapted to and validated for the Spanish
population is indispensable for lending credibility to and
standardizing the results obtained.
Although there is abundant international research in
this field [2,3], the results might not be wholly applic-
able to our patients, since perception of HRQL is linked
to an immediate reality that is specific to the woman
who has the disease. Accordingly, our study comple-
ments an important review by Montazeri [3], which
excluded papers not written in English. The concept of
HRQL depends on cultural norms, behaviour patterns,
and personal expectations [72]. It presupposes the ability
to make a cultural synthesis of all the elements regarded
by a given society as making up its pattern of comfort
and wellbeing [73]. Moreover, it is reasonable to assume
that if there are socio-cultural and health care differ-
ences there will also be differences in assessment of
HRQL among breast cancer patients in different coun-
tries, as has been shown in the case of other tumours
[74]. In this respect, attention should be drawn to the
fact that international studies do not routinely furnish
comparative information on HRQL stratified by country.
This paper is the first one to include articles in
Spanish about studies on the quality of life of women
with breast cancer, not included in previous reviews.
The comprehensive search performed, which included
international as well as national bibliographic databases,
as well as the review process have been performed fol-
lowing PRISMA statement criteria. However, we could
not perform a meta-analysis due to the small number of
Delgado-Sanz et al. Health and Quality of Life Outcomes 2011, 9:3
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results. Additionally, the exclusion of some international
studies[62-64] due to the inclusion criteria adopted
could be seen as a limitation of the review in its goal to
reflect the research made in Spain on HRQL in Breast
Cancer patients.
In brief, there is clearly insufficient information avail-
able on the HRQL of Spanish women with breast can-
cer. Since HRQL is one of the principal result indicators
for improving the care of and evaluating new treatments
for such patients, encouragement should be given to
promoting research and publication in this field.
Additional material
Additional file 1: Studies on quality of life and breast cancer among
Spanish women (1993-2009): basic characteristics and summary of
principal results.
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